As systemic blastomycosis is a relatively uncommon, but frequently fatal, disease for which no satisfactory treatment has been available, the need for evaluation of new methods of therapy is evident. The fungistatic properties of the diamidines in vitro was noted by Elson.1 The successful clinical use of Stilbamidine (4,4′-stilbenedicarboxamidine) and Propamidine (4,4′diamidinodi-odiphenoxypropane dihydrochloride) in the treatment of a single case of blastomycosis was reported by Schoenbach and co-workers.2 As further evidence of the effectiveness of Stilbamidine, the following case is reported. In this case Stilbamidine alone was used without adjuvant therapy and was given continuously as a single course over a prolonged period. For the sake of brevity only data pertinent to the diagnosis and treatment of blastomycosis will be given.
REPORT OF A CASE
A 53-year-old Negro man had lesions that began in March, 1948, on the face and then spread to the neck, back, chest, forearms,
Pariser H, Levy ED, Rawson AJ. TREATMENT OF BLASTOMYCOSIS WITH STILBAMIDINE: REPORT OF A CASE. JAMA. 1953;152(2):129–130. doi:10.1001/jama.1953.63690020003004a
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: